GlassScriptPhysician profile
Joel S Crockett
NPI 1316174956
$15,865.04
in general payments reported to CMS, 2019-2025
31 companies · $3,561 in 2025
The $3,561 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $668 · 2021: $1,167 · 2022: $1,824 · 2023: $3,440 · 2024: $3,951 · 2025: $3,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $34.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,917.25 |
| Education | $34.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,133.73 | 2019-2025 | Skyrizi, Humira, Rinvoq |
| Janssen Biotech, INC. | $2,142.99 | 2020-2025 | Tremfya, Remicade, Stelara |
| Lilly USA, LLC | $1,294.99 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,138.42 | 2019-2025 | |
| Leo Pharma INC. | $1,109.13 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $936.72 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $766.08 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $731.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $421.62 | 2022-2025 | Sotyktu |
| Pfizer INC. | $414.07 | 2019-2025 | |
| Dermavant Sciences, INC. | $412.18 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $400.67 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $351.23 | 2019-2025 | |
| Amgen INC. | $348.96 | 2019-2024 | Otezla |
| Galderma Laboratories, L.P. | $309.31 | 2019-2025 | Nemluvio, Aklief |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $175.28 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $137.85 | 2019-2020 | |
| Ucb, INC. | $134.83 | 2022-2025 | Bimzelx |
| Biofrontera INC. | $104.27 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $49.35 | 2023 | Valchlor |
| Celgene Corporation | $44.68 | 2019 | |
| Organon LLC | $34.37 | 2025 | Vtama |
| Mimedx Group, INC. | $30.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.79 | 2023 | Cyltezo |
| Cipher Pharmaceuticals US LLC | $24.81 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $24.58 | 2025 | Ycanth |
| Organogenesis INC. | $22.62 | 2024 | Cygnus Dual |
| Dermira, INC. | $22.47 | 2020 | |
| Almirall LLC | $21.38 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.42 | 2025 | Siliq, Jublia, Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Crockett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.